In July 1998, the FDA approved Celgene’s request to market and sell their thalidomide drug “Thalomid” for the treatment of ENL (Erythema Nodosum Leprosum, a severe and debilitating condition associated with leprosy). Celgene had developed a strict prescribing system which imposed tough safeguards to make sure the drug wouldn’t be taken by pregnant women. (Later Celgene was allowed to market their Thalidomide preparations for other applications as well, for example in the treatment of multiple myeloma.)

Source: Financial Times: “Thalidomide: Not over yet”, September 21, 2007